Anders, Hans-Joachim et al. published their research in Clinical Journal of the American Society of Nephrology in 2021 | CAS: 1346623-17-3

(2R,3S)-2-(4-(Cyclopentylamino)phenyl)-1-(2-fluoro-6-methylbenzoyl)-N-(4-methyl-3-(trifluoromethyl)phenyl)piperidine-3-carboxamide (cas: 1346623-17-3) belongs to piperidine derivatives. Piperidine is a metabolite of cadaverine, a polyamine found in the human intestine. Piperidine derivatives bearing a masked aldehyde function in the 蔚-position are easily transformed into quinolizidine compounds through intramolecular reductive amination.Recommanded Product: (2R,3S)-2-(4-(Cyclopentylamino)phenyl)-1-(2-fluoro-6-methylbenzoyl)-N-(4-methyl-3-(trifluoromethyl)phenyl)piperidine-3-carboxamide

Being an ADVOCATE for people with ANCA vasculitis was written by Anders, Hans-Joachim;Nakazawa, Daigo. And the article was included in Clinical Journal of the American Society of Nephrology in 2021.Recommanded Product: (2R,3S)-2-(4-(Cyclopentylamino)phenyl)-1-(2-fluoro-6-methylbenzoyl)-N-(4-methyl-3-(trifluoromethyl)phenyl)piperidine-3-carboxamide This article mentions the following:

The phase 3 clin. trial of avacopan in patients with ANCA-associated vasculitis (ADVOCATE) now reports phase 3 trial results in 331 patients with ANCA vasculitis. Eligible patients had newly diagnosed or relapsing ANCA vasculitis including granulomatosis with polyangiitis and microscopic polyangiitis, with eGFR>15 mL/min per 1.73 nr. All patients received either cyclophosphamide (followed by azathioprine) or rituximab and participants were assigned to receive either oral avacopan at a dose of 30 mg twice daily or oral prednisone on a tapering schedule. Tlie first and second primary end points were remission at week 26 and sustained remission at both weeks 26 and 52, resp. Therates of serious adverse events in the avacopan and prednisone groups (excluding worsening vasculitis) were 37.3% and 39.0%, resp. In the experiment, the researchers used many compounds, for example, (2R,3S)-2-(4-(Cyclopentylamino)phenyl)-1-(2-fluoro-6-methylbenzoyl)-N-(4-methyl-3-(trifluoromethyl)phenyl)piperidine-3-carboxamide (cas: 1346623-17-3Recommanded Product: (2R,3S)-2-(4-(Cyclopentylamino)phenyl)-1-(2-fluoro-6-methylbenzoyl)-N-(4-methyl-3-(trifluoromethyl)phenyl)piperidine-3-carboxamide).

(2R,3S)-2-(4-(Cyclopentylamino)phenyl)-1-(2-fluoro-6-methylbenzoyl)-N-(4-methyl-3-(trifluoromethyl)phenyl)piperidine-3-carboxamide (cas: 1346623-17-3) belongs to piperidine derivatives. Piperidine is a metabolite of cadaverine, a polyamine found in the human intestine. Piperidine derivatives bearing a masked aldehyde function in the 蔚-position are easily transformed into quinolizidine compounds through intramolecular reductive amination.Recommanded Product: (2R,3S)-2-(4-(Cyclopentylamino)phenyl)-1-(2-fluoro-6-methylbenzoyl)-N-(4-methyl-3-(trifluoromethyl)phenyl)piperidine-3-carboxamide

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem